Alectinib: a targeted treatment option for ALK-positive non-small cell lung cancer

Alectinib is a second-generation targeted drug for ALK-positive non-small cell lung cancer (NSCLC). It blocks tumor growth signals by inhibiting ALK protein kinase activity. This article will start with its mechanism of action, clinical advantages, applicable groups and production information to help patients fully understand this treatment option. The main content includes: 1) The core working principle of drugs; 2) Comparing the efficacy and safety advantages of first-generation drugs; 3) Applicable patient screening criteria; 4) Domestic and foreign manufacturers and drug names.

Precisely block the molecular mechanism of tumor growth

As a tyrosine kinase inhibitor, aletinib is unique in that it can highly selectively bind to ALK fusion proteins and inhibit the downstream STAT3 and PI3K/AKT pathways. Compared with the first-generation drug crizotinib, its affinity for the ALK target is increased by 5 times, and it can effectively penetrate the blood-brain barrier and show significant control effects on brain metastases. Clinical studies show that alectinib can increase the median progression-free survival (PFS) of patients with ALK-positive NSCLC to 34.8 months, which is significantly longer than that of the control group.

Double breakthrough in efficacy and safety

In the ALEX phase III clinical trial, the 3-year survival rate of patients in the alectinib group reached 62.5%, and the risk of brain metastasis was reduced by 84%. The incidence of adverse reactions is lower than that of first-generation drugs, and common side effects such as fatigue (28%) and constipation (20%) are mostly grade 1-2. Different from traditional chemotherapy, this drug does not cause significant bone marrow suppression, and the patient's quality of life score improves by 37% (based on the EORTC QLQ-C30 scale). These data make it a priority recommendation in the NCCN guidelines.

Patients benefiting from precision medicine

Applicable patients need to be confirmed positive for ALK rearrangement by FISH or NGS testing, and are especially suitable for: 1) patients with newly treated advanced NSCLC; 2) patients who have progressed after resistance to crizotinib; 3) patients with asymptomatic brain metastases. It should be noted that the efficacy of patients with coexisting EGFR mutations may be limited. Liver function should be assessed before medication (ALT needs to be <2.5 times ULN). The standard daily dose is 600mg bid. Taking it with meals can increase bioavailability by 20%.

Global production and drug information summary

An important choice in the era of personalized treatment

Alectinib represents a major advance in targeted therapy for ALK-positive NSCLC, with long-lasting disease control and good tolerability balancing efficacy and quality of life. Patients must strictly follow genetic testing instructions when taking medications, and regularly monitor CPK levels and vision changes. As more real-world data accumulates, the value of this drug in sequential treatment will be further clarified, providing a new paradigm for the chronic disease management of lung cancer.

Data source:
1. NCCN Clinical Practice Guidelines (2023 v1)
2. ALEX clinical trial (NCT02075840)
3. National Medical Products Administration drug database
4. Roche Pharmaceutical Product Instructions (2022 Edition)